BRIEF published on 04/21/2026 at 15:14, 10 days 8 hours ago MaaT Pharma SACA Maintains Buy Rating with Stable Financial Outlook Financial Performance BUY Rating Pipeline Development MaaT Pharma Investment Case
PRESS RELEASE published on 04/21/2026 at 15:09, 10 days 8 hours ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research reaffirms Buy rating for MaaT Pharma SACA with a target price of €17 following FY25 results and pipeline update. No changes to core investment case First Berlin Equity Research BUY Rating MaaT Pharma SACA FY25 Results €17 Target Price
BRIEF published on 04/01/2026 at 07:35, 1 month ago MaaT Pharma publishes data on aGvH in "Bone Marrow Transplantation" MaaT Pharma EMA AGvH Xervyteg® CHRONOS
BRIEF published on 04/01/2026 at 07:35, 1 month ago MaaT Pharma Presents CHRONOS Study Results on Third-Line Acute GvHD MaaT Pharma Regulatory Review CHRONOS Study Acute GvHD Third-line Therapy
PRESS RELEASE published on 04/01/2026 at 07:30, 1 month ago Inside Information / Other news releases MaaT Pharma announces publication of retrospective data from CHRONOS study in Bone Marrow Transplantation Journal, presenting real-world outcomes of third-line systemic treatments for GI-aGvHD patients MaaT Pharma GI-aGvHD CHRONOS Study Retrospective Data Bone Marrow Transplantation
BRIEF published on 03/31/2026 at 07:35, 1 month 1 day ago MaaT Pharma: 2025 Revenue and Clinical Progress Revenue Funding Clinical Development MaaT Pharma Microbiothérapies
BRIEF published on 01/20/2026 at 18:35, 3 months 12 days ago MaaT Pharma Launches Phase 2 Trial for NSCLC Patients NSCLC MaaT Pharma Gut Microbiome IMMUNOLIFE Phase 2 Antibiotic-induced Dysbiosis
PRESS RELEASE published on 01/20/2026 at 18:30, 3 months 12 days ago Inside Information / Other news releases MaaT Pharma announces first patient randomized in IMMUNOLIFE Phase 2 study sponsored by Gustave Roussy to explore the role of gut microbiome in overcoming ICI resistance in NSCLC patients with antibiotic-induced dysbiosis NSCLC MaaT Pharma Gut Microbiome Antibiotic-induced Dysbiosis IMMUNOLIFE
BRIEF published on 12/10/2025 at 11:30, 4 months 22 days ago MaaT Pharma SACA Maintains Positive Outlook as Phase 3 Trial Data Strengthens Buy Recommendation Phase 3 Trial MaaT Pharma Xervyteg GI-aGvHD
PRESS RELEASE published on 12/10/2025 at 11:25, 4 months 22 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates recommendation to BUY for MaaT Pharma SACA with a target price of €17 following positive phase 3 trial results for Xervyteg presented at ASH Annual Meeting 2025 First Berlin Equity Research Buy Recommendation ASH Annual Meeting Xervyteg MaaT Pharma SACA
Published on 05/01/2026 at 22:30, 1 hour 26 minutes ago Nextech3D.ai Appoints New Independent Auditor
Published on 05/01/2026 at 22:30, 1 hour 26 minutes ago Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing
Published on 05/01/2026 at 22:30, 1 hour 26 minutes ago Apex Critical Metals Announces Extension of Marketing Agreement with Rumble Strip Media Inc.
Published on 05/01/2026 at 18:00, 5 hours 56 minutes ago Star Copper to Present at the Emerging Growth Conference on May 7, 2026
Published on 05/01/2026 at 15:35, 8 hours 21 minutes ago LNG Energy Group Announces Partial Revocation of Cease Trade Order and Proposed Private Placement
Published on 05/01/2026 at 19:23, 4 hours 33 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 17:45, 6 hours 10 minutes ago Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 6 hours 34 minutes ago Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 04/30/2026 at 20:00, 1 day 3 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 4 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 4 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 5 hours ago Minutes of the Combined General Meeting held on April 30, 2026
